RxDoctor Payments Data

Shannon Stone, NP

Family · Saluda, VANPI 1689066292

Payments from drug & device makers

$644in general payments, 2019–2025

Across 20 payments — averaging $32.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$259
  • AstraZeneca$125
  • Novo Nordisk$104
  • Pfizer$34
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$31
  • Otsuka America Pharmaceutical, Inc.$22
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$644100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$644 in reported general payments places this provider in the 60th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$38,318
Medicare patients
99
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$40,293
TrulicityDulaglutide25$40,182
OzempicSemaglutide33$33,893
MounjaroTirzepatide20$21,671
EliquisApixaban27$21,208
CaplytaLumateperone Tosylate11$17,985
LinzessLinaclotide17$11,860
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,141
Tresiba Flextouch U-100Insulin Degludec15$7,405
DuleraMometasone/Formoterol12$4,630
Pregabalin39$2,128
Dexlansoprazole DrDexlansoprazole11$1,808
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$1,708
Fluoxetine Hcl75$1,462
Gabapentin137$1,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$18$61,85345 claims
Novo NordiskOzempic$104$33,89333 claims
PfizerEliquis$34$21,20827 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$31$17,98511 claims
AbbVieLinzess$259$11,86017 claims
AstraZenecaBreztri Aerosphere$125$10,14116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,332 family providers in Virginia.

Other family in Saluda

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →